Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|ClinicalTrials.gov Identifier: NCT00003538|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : May 2, 2014
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Stem cells that have been treated in the laboratory to remove lymphocytes may prevent this from happening.
PURPOSE: Clinical trial to prevent graft-versus-host disease in patients undergoing bone marrow transplantation.
|Condition or disease||Intervention/treatment|
|Cancer||Biological: graft versus host disease prophylaxis/therapy Procedure: allogeneic bone marrow transplantation|
- Determine whether stem cell augmented, elutriated grafts prevent graft versus host disease in patients undergoing allogeneic bone marrow transplantation.
OUTLINE: Patients receive elutriated CD34+ augmented donor bone marrow on day 0.
Bone marrow samples are obtained before day 100, around 6 months, and 1 year after transplant.
PROJECTED ACCRUAL: Not specified
|Study Type :||Interventional (Clinical Trial)|
|Primary Purpose:||Supportive Care|
|Official Title:||Stem Cell Augmented, Elutriated Grafts for Allogeneic Bone Marrow Transplantation|
|Study Start Date :||March 1997|
|Primary Completion Date :||May 2004|
|Study Completion Date :||May 2004|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003538
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21231-2410|
|Study Chair:||Richard J. Jones, MD||Sidney Kimmel Comprehensive Cancer Center|